openPR Logo
Press release

Lassa Fever Treatment Market Will Expand Due To Awareness Among People About The Disease Is Expected To Drive | Hoffmann-La Roche , Mylan N.V

12-01-2023 03:20 AM CET | Health & Medicine

Press release from: Global Insight Services

Lassa fever is a viral hemorrhagic fever caused by the Lassa virus, a member of the arenavirus family of viruses. It is endemic in parts of West Africa, where it is one of the most common causes of viral hemorrhagic fever. The virus is transmitted to humans from contact with food or household items contaminated with rodent excreta.

Download Free Sample of Report - https://www.globalinsightservices.com/request-sample/GIS26132/?utm_source=pranalipawar&utm_medium=Openpr&utm_campaign=01122023

The mainstay of treatment for Lassa fever is supportive care, which includes maintaining adequate hydration and electrolyte balance, as well as controlling fever and other symptoms. Patients may also require oxygen therapy, blood transfusions, and mechanical ventilation.

Antiviral medications may be used to treat Lassa fever, however, they are not always effective. Ribavirin is the only antiviral drug approved for the treatment of Lassa fever and it is most effective when it is started early in the course of the illness. It is usually administered intravenously and can cause significant side effects, including anemia and liver damage.

In severe cases, immunoglobulin therapy may be used to provide passive immunity against the virus. This is an infusion of antibodies from individuals who have recovered from Lassa fever, which can help to boost the patient's own immune system.

In the most severe cases, patients may require intensive care, including dialysis and organ support. The mortality rate of Lassa fever can be as high as 80%, so early diagnosis and treatment is essential.

Report Overview- https://www.globalinsightservices.com/reports/lassa-fever-treatment-market//?utm_source=pranalipawar&utm_medium=Openpr&utm_campaign=01122023

To prevent the spread of Lassa fever, it is important to practice good hygiene and take precautions when encountering rodents, such as wearing protective gloves and masks. Vaccines are currently under development, but are not yet available.

Key Trends

Lassa fever is a viral hemorrhagic fever caused by the Lassa virus, an arenavirus from the family Arenaviridae. It is endemic in a number of West African countries, including Nigeria, Liberia, Sierra Leone, and Guinea, and is one of the most important emerging infectious diseases in the region. Treatment of Lassa fever is challenging, as it is often difficult to diagnose and requires a combination of supportive care and antiviral medications. In recent years, there has been a growing focus on developing new treatments and technologies for the management of Lassa fever. In this article, we will discuss the key trends in Lassa fever treatment technology.

Diagnostics: The first trend in Lassa fever treatment technology is the development of new diagnostic tools. Currently, the gold standard for diagnosing Lassa fever is the reverse transcriptase-polymerase chain reaction (RT-PCR) test. However, this test is expensive and time-consuming, and is not widely available in resource-limited settings. To address this limitation, researchers are developing new, rapid point-of-care diagnostic tests that can be used in the field. These tests use a combination of antibody-based and molecular techniques to quickly detect the presence of the virus in a patient sample.
Vaccines: The second trend is the development of vaccines to prevent Lassa fever. Vaccines are an important tool for controlling and preventing the spread of infectious diseases, and a number of vaccine candidates have been developed for Lassa fever. These candidates are being evaluated in clinical trials, and if successful, could provide an important tool for controlling and preventing the spread of the disease.
Antiviral Drugs: The third trend is the development of new antiviral drugs for the treatment of Lassa fever. Currently, ribavirin is the only approved antiviral drug for the treatment of Lassa fever. However, ribavirin is not always effective and can cause serious side effects. To address this limitation, researchers are developing new antiviral drugs that are more effective and have fewer side effects.
Supportive Care: The fourth trend is the development of new supportive care strategies for Lassa fever. Supportive care is an important part of the treatment of Lassa fever, as it can reduce the severity of symptoms and improve patient outcomes. New supportive care strategies are being developed, such as the use of intravenous fluids and oxygen, as well as medications to reduce fever and other symptoms.

Get a customized scope to match your need, ask an expert - https://www.globalinsightservices.com/request-customization/GIS26132/?utm_source=pranalipawar&utm_medium=Openpr&utm_campaign=01122023

Overall, there is a growing focus on developing new treatments and technologies for the management of Lassa fever. New diagnostic tools, vaccines, antiviral drugs, and supportive care strategies are being developed to improve the diagnosis, prevention, and treatment of this important emerging infectious disease.

Key Drivers

Lassa fever is an acute viral hemorrhagic illness caused by the Lassa virus, which is a member of the family Arenaviridae. It is endemic in West Africa, where it is responsible for a significant amount of morbidity and mortality each year. The disease is transmitted from person to person, mainly through contact with infected rodents, or their secretions and excretions.

The key drivers of the Lassa fever treatment market are increasing prevalence of the disease, rising awareness among people, growing investments in research and development activities, and increasing government initiatives. According to the World Health Organization (WHO), the global prevalence of Lassa fever is about 300,000 cases annually. This is expected to drive the demand for Lassa fever treatments.

Moreover, increasing awareness among people about the disease is expected to drive the demand for Lassa fever treatments. Several campaigns and initiatives are being undertaken by government organizations and non-governmental organizations to spread awareness about the disease. This is expected to drive the demand for treatments.

Furthermore, investments in research and development activities related to Lassa fever treatments are expected to drive the market. Pharmaceutical companies are investing in research and development activities to develop effective drugs to treat Lassa fever. This is expected to drive the demand for Lassa fever treatments.

Additionally, government initiatives are expected to drive the market. Governments of several countries are taking initiatives to reduce the burden of the disease. For instance, the government of Nigeria has set up a task force to address Lassa fever. This is expected to drive the demand for treatments.

Overall, the increasing prevalence of the disease, rising awareness among people, growing investments in research and development activities, and increasing government initiatives are the key drivers of the Lassa fever treatment market.

.Market Segmentation

The market can be segmented by dosage form, treatment, route of administration, end-users, and region. By Dosage Form, the market can be divided into Ribavirin Tablets, Ribavirin Inhalation solution, and Ribavirin Oral solution. By Treatment, the market can be divided into Antiviral, Supportive Care, and Others. By Route of Administration, the market can be divided into Oral and Others. By End-Users, the market can be divided into Hospitals, Homecare, Specialty Clinics, and Others. By region, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World.

Buy Now - https://www.globalinsightservices.com/checkout/single_user/GIS26132/?utm_source=pranalipawar&utm_medium=Openpr&utm_campaign=01122023

Key Players

The market includes players such as AstraZeneca (U.K.), Lilly (U.S.), Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), and Merck & Co., Inc. (U.S.).

 With Global Insight Services, you receive:

10-year forecast to help you make strategic decisions
In-depth segmentation which can be customized as per your requirements
Free consultation with lead analyst of the report
Excel data pack included with all report purchases
Robust and transparent research methodology

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lassa Fever Treatment Market Will Expand Due To Awareness Among People About The Disease Is Expected To Drive | Hoffmann-La Roche , Mylan N.V here

News-ID: 3311297 • Views:

More Releases from Global Insight Services

Immuno Oncology Drugs Market Projected to Reach $634.1 Billion by 2034, Growing at 17.5% CAGR | Overall Study Report
Immuno Oncology Drugs Market Projected to Reach $634.1 Billion by 2034, Growing …
The Immuno Oncology Drugs Market is rapidly emerging as a transformative segment in the global healthcare industry. These drugs harness the body's immune system to identify and attack cancer cells, offering innovative treatment alternatives to traditional chemotherapy and radiation therapies. Immuno-oncology therapies include monoclonal antibodies, checkpoint inhibitors, cancer vaccines, and cell-based therapies such as CAR-T cells. The growth of this market is primarily driven by advancements in biotechnology, an improved
GLP 1 Market Projected to Reach $221.8 Billion by 2034, Growing at 9% CAGR | Overall Study Report
GLP 1 Market Projected to Reach $221.8 Billion by 2034, Growing at 9% CAGR | Ove …
The GLP 1 Market is experiencing unprecedented growth, fueled by the rising prevalence of type 2 diabetes and obesity globally. GLP-1, or glucagon-like peptide-1 receptor agonists, represents a groundbreaking therapeutic class that improves insulin secretion, reduces glucagon production, and slows gastric emptying. These mechanisms not only enhance glycemic control but also support weight management, making GLP-1 therapies a preferred choice among healthcare providers and patients alike. Over the years, the
Autonomous Bus Market to Expand to $11.6 Billion by 2034, Advancing at 18.8% CAGR | Key Players: EasyMile, Navya, Aurrigo
Autonomous Bus Market to Expand to $11.6 Billion by 2034, Advancing at 18.8% CAG …
Market Overview Autonomous Bus Market is revolutionizing the future of urban mobility through advanced automation technologies. Valued at $2.1 billion in 2024, the market is projected to reach $11.6 billion by 2034, expanding at a strong CAGR of 18.8%. This market focuses on the development and deployment of self-driving buses equipped with cutting-edge sensors, artificial intelligence, and vehicle-to-everything (V2X) communication systems. These buses are designed to improve road safety, enhance passenger
Automotive Tire Market to Attain $976.7 Billion by 2034, Growing at 9.2% CAGR | Key Players: Apollo Tyres, Nokian Tyres, Hankook Tire
Automotive Tire Market to Attain $976.7 Billion by 2034, Growing at 9.2% CAGR | …
Market Overview Automotive Tire Market is experiencing remarkable growth as the industry embraces innovation, sustainability, and digital transformation. Valued at $406 billion in 2024, the market is projected to soar to $976.7 billion by 2034, reflecting a CAGR of 9.2%. This expansion is primarily driven by the surge in global vehicle production, growing consumer preference for durable and high-performance tires, and the increasing adoption of smart tire technologies. The Automotive Tire

All 5 Releases


More Releases for Lassa

Lassa Fever Market Insights Highlight Expanding Outlook Till 2034, DelveInsight …
The Lassa Fever market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lassa Fever pipeline products will significantly revolutionize the Lassa Fever market dynamics. DelveInsight's "Lassa Fever Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lassa Fever, historical and forecasted epidemiology as well as the Lassa Fever market trends in the United
Lassa fever market is expected to reach USD 210 million by 2034
Lassa fever is an acute viral hemorrhagic illness caused by the Lassa virus, an arenavirus endemic to West Africa. It spreads primarily through contact with food or household items contaminated by rodents (Mastomys natalensis) or through person-to-person transmission in healthcare settings. With an estimated 100,000-300,000 infections annually and ~5,000 deaths, Lassa fever poses a serious public health threat. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71747 Currently, there is no approved
Lassa Fever Treatment Market, Unraveling Innovations and Strategic Solutions for …
Overview of the Lassa Fever Treatment Market The global Lassa fever treatment market has been rapidly gaining traction as the prevalence of this viral disease continues to impact public health worldwide. Lassa fever is an acute viral hemorrhagic disease caused by the Lassa virus, primarily transmitted by rodents, particularly the Mastomys species, which are found in parts of West Africa. While Lassa fever has a relatively low mortality rate compared to
Lassa Fever Market Size, Analysis, Industry Statistics and Latest Insights Till …
Market Overview: The lassa fever market is expected to exhibit a CAGR of 3.84% during 2023-2033. The lassa fever market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the
Lassa Fever Treatment Market Trends, Growth Development, Key Opportunity, Applic …
When building an excellent  Lassa Fever Treatment Market report, myriad of objectives of the marketing research have been kept in mind. All the data and statistics included in this report is derived from the reliable sources only e.g. journals or white papers of companies etc. This market research report contains several parameters which are thoroughly studied by the experts. This market analysis report provides with a thorough analysis of market
Lassa Fever Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Lassa Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Lassa Fever Market , historical and forecasted epidemiology as well as the Lassa Fever Market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Lassa Fever Market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Lassa Fever